Black Rock Inc. Adial Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.21 - $0.37 $6,613 - $11,651	-31,491 Reduced 13.94%	194,364 $40,000
Q1 2023 May 12, 2023	BUY	$0.24 - $0.56 $272 - $635	1,134 Added 0.5%	225,855 $79,000
Q4 2022 Feb 13, 2023	BUY	$0.2 - $0.31 $151 - $234	756 Added 0.34%	224,721 $49,000
Q3 2022 Nov 14, 2022	SELL	$0.03 - $0.58 $28 - $548	-945 Reduced 0.42%	223,965 $79,000
Q2 2022 Aug 12, 2022	SELL	N/A	-567 Reduced 0.25%	224,910 $301,000

Q1 2022 May 12, 2022	SELL	N/A	-1,701 Reduced 0.75%	225,477 $454,000
Q4 2021 Feb 10, 2022	BUY	N/A	31,923 Added 16.35%	227,178 $613,000
Q3 2021 Nov 09, 2021	SELL	N/A	-656 Reduced 0.33%	195,255 $837,000
Q2 2021 Aug 11, 2021	BUY	N/A	195,911 New	195,911 $499,000

5.5K

Ticker ADIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,854,000
Market Cap $28.2M
Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focu...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.